Lynx1 Capital Management LP Diversified Active

CIK: 0001910456 · Show all filings

Period: Q2 2023 (← Previous) (Next →)

Filing Date: Aug 14, 2023

Total Value ($000): $152,625 (100.0% shares, 0.0% debt)

Holdings (18)

MERUS N V 19.9%
Value ($000) $30,346 Shares 1,152,525 Est. Cost $24.66 Unrealized
CABA CABALETTA BIO INC 18.5%
Value ($000) $28,162 Shares 2,181,377 Est. Cost $3.64 Unrealized +198.1%
ALPINE IMMUNE SCIENCES INC 18.0%
Value ($000) $27,452 Shares 2,670,472 Est. Cost $10.20 Unrealized
CYMABAY THERAPEUTICS INC 8.6%
Value ($000) $13,195 Shares 1,205,050 Est. Cost $3.16 Unrealized
TCRX TSCAN THERAPEUTICS INC 8.6%
Value ($000) $13,062 Shares 5,224,600 Est. Cost $2.68 Unrealized 0.0%
GHRS GH RESEARCH PLC 7.5%
Value ($000) $11,502 Shares 969,374 Est. Cost $10.26 Unrealized 0.0%
PARDES BIOSCIENCES INC 4.6%
Value ($000) $7,063 Shares 3,902,434 Est. Cost $5.14 Unrealized
THESEUS PHARMACEUTICALS INC 4.6%
Value ($000) $7,063 Shares 757,009 Est. Cost $8.59 Unrealized
KINNATE BIOPHARMA INC 4.1%
Value ($000) $6,208 Shares 2,048,736 Est. Cost $10.62 Unrealized
NEOLEUKIN THERAPEUTICS INC 1.7%
Value ($000) $2,568 Shares 3,094,554 Est. Cost $0.59 Unrealized
PIERIS PHARMACEUTICALS INC 1.1%
Value ($000) $1,618 Shares 9,775,849 Est. Cost $1.23 Unrealized
CGEM CULLINAN ONCOLOGY INC 0.8%
Value ($000) $1,238 Shares 115,063 Est. Cost $10.62 Unrealized 0.0%
PASSAGE BIO INC 0.7%
Value ($000) $1,099 Shares 1,167,343 Est. Cost $1.43 Unrealized
GPCR STRUCTURE THERAPEUTICS INC 0.6%
Value ($000) $956 Shares 23,000 Est. Cost $23.79 Unrealized
ATHIRA PHARMA INC 0.4%
Value ($000) $571 Shares 193,573 Est. Cost $2.95 Unrealized
PHVS PHARVARIS N V 0.2%
Value ($000) $321 Shares 21,225 Est. Cost $5.38 Unrealized +79.0%
CMPS COMPASS PATHWAYS PLC 0.1%
Value ($000) $167 Shares 20,114 Est. Cost $8.28 Unrealized
DBV TECHNOLOGIES S A 0.0%
Value ($000) $35 Shares 18,265 Est. Cost $1.90 Unrealized